Categories AlphaGraphs, Earnings, Health Care

A visual dashboard of AbbVie’s Q1 2020 earnings results

AbbVie (NYSE: ABBV) reported its first quarter 2020 earnings results, which surpassed the market’s views. Adjusted EPS of $2.42 and revenue of $8.62 billion, topped analysts’ EPS target of $2.25 and revenue target of $8.33 billion. For fiscal 2020, the drug manufacturer lifted its 2020 GAAP EPS outlook, while reaffirmed the non-GAAP EPS target. ABBV stock rose about 1% in the pre-market session.

AbbVie (ABBV) Q1 2020 earnings review

AbbVie lifted its standalone GAAP EPS guidance for the full-year 2020 to $7.66 to $7.76 from an earlier range of $7.60 to $7.70, representing growth of 44.9% at the midpoint and confirmed the previous expectation of standalone adjusted diluted EPS of $9.61 to $9.71, representing growth of 8.1% at the midpoint.

[irp posts=”51574″]

AbbVie has initiated the Phase 2 iNSPIRE clinical trial to evaluate the potential of IMBRUVICA drug to treat patients with moderate to severe COVID-19. AbbVie is also supporting COVID-19 clinical research by collaborating with health authorities and institutions globally to determine antiviral activity as well as efficacy and safety of KALETRA/ALUVIA, the company’s antiretroviral therapy for the treatment of HIV, against COVID-19.

After reaching a 52-week high ($97.86) February 12, ABBV stock fell to its yearly low ($62.55) on March 23. ABBV shares have retreated 7% since the beginning of this year.

Most Popular

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Target (TGT): A look at some of the challenges faced by the retailer in 3Q24

Shares of Target Corporation (NYSE: TGT) stayed green on Thursday, recovering from the stumble it took a day ago after delivering disappointing results for the third quarter of 2024 and

Comments

  1. Pingback: Bulk URL Shortener
  2. Pingback: Bulk URL Shortener
  3. Pingback: masumintl.com
  4. Pingback: masumintl
  5. Pingback: ItMe.Xyz
  6. Pingback: Bokeo Thailand
Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top